Recently, FOURIER trial and ODYSSEY OUTCOMES trial have confirmed that PCSK9 inhibitors reduce major adverse cardiovascular and cerebrovascular events in patients with ASCVD compared with the placebo group [15, 16]. The gene discussed is PCSK9; the disease is atherosclerosis.